Skip to content
Screener

Long-Term Debt at other companies

Eli Lilly logo
Eli LillyLLY
$47.86B+40.0%
TG Therapeutics logo
TG TherapeuticsTGTX
$745.39M+204%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$45M
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0-100%
XER
Xeris Biopharma Holdings, Inc.XERS
$188.81M-13.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$60.1M+83.8%
Gross profit$53.0M+82.3%
Operating income-$52.4M-11.4%
Net income-$55.6M-12.4%
EPS (diluted)-$0.83-2.5%

Balance sheet

See full
Cash & equivalents$62.1M-41.4%
Total debt$112.3M-1.1%
Total equity$122.9M+549%
Total assets$442.3M+14.4%

Cash flow

See full
Operating cash flow-$44.2M-9.5%
CapEx$238.3K
Free cash flow-$29.2M-2.4%

Valuation

See full
Market cap$7.62B+27.5%
Enterprise value$7.67B+28.8%
P/S35.1×-3.2×

Profitability

See full
Gross margin89.4%-0.2pp
Operating margin-90.9%-19.8pp
Net margin-93.3%-18.2pp
FCF margin-61.5%-14.1pp

Returns & leverage

See full
Return on equity-285.8%-68.9pp
Debt / equity0.9×-5.1×
Current ratio4.2×+0.9×

Where this comes from

Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.

The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-030549
Line itemMarch 31,2026December 31,2025
Deferred royalty obligation, current10,1307,296
Total current liabilities103,198105,942
Long-term liabilities:
Deferred royalty obligation98,339100,886
Lease liability, non-current3,1633,342
Total liabilities204,700210,170
Commitments and contingencies (Note 14)
Series A convertible preferred stock, $0.001 par value: 150,000 shares authorized; 115,000 and 132,500 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively. Liquidation preference of $115,000 and $132,500 as of March 31, 2026, and December 31, 2025, respectively.114,710130,957

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Rhythm Pharmaceuticals, Inc.'s long-term debt?
Rhythm Pharmaceuticals, Inc. (RYTM) reported long-term debt of $98.34M in Q1 2026.
How has Rhythm Pharmaceuticals, Inc.'s long-term debt changed year-over-year?
Rhythm Pharmaceuticals, Inc.'s long-term debt decreased by 8.9% year-over-year, from $107.93M to $98.34M.
What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s long-term debt?
Over 2 years (2023 to 2025), Rhythm Pharmaceuticals, Inc.'s long-term debt has grown at a -2.5% compound annual growth rate (CAGR), from $106.14M to $100.89M.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.

Ask your AI about Rhythm Pharmaceuticals, Inc.'s long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude